Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05375994 · ClinicalTrials.gov registry record · Phase 1
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
A Phase 1 study of Non-Small Cell Lung Cancer and Advanced Cancer, sponsored by Verastem.
- Active
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 8
- Study locations
NCT05375994 is a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Cancer that is active but no longer recruiting, run by Verastem. The registered enrollment target is 85 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT05375994, a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Cancer, is active but no longer recruiting, sponsored by Verastem.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Conditions Studied
Interventions
- DRUG avutometinib (VS-6766) and adagrasib
Study Locations (8)
California
- UCSF Thoracic Oncology - San Francisco
Colorado
- University of Colorado Hospital Anschutz Cancer Pavllion - Aurora
Florida
- Mayo Clinic Cancer Center - Jacksonville
Minnesota
- Mayo Clinic Cancer Center - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Virginia
- Virginia Cancer Specialists, NEXT Oncology - Fairfax
Wisconsin
- Medical College Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2026-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05375994
The ClinicalTrials.gov registry entry for NCT05375994 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which avutometinib (VS-6766) and adagrasib is the first listed.
NCT05375994 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05375994 about?
NCT05375994 is a clinical study titled "Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients". This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
What is the current status of trial NCT05375994?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2022-08-01. Estimated completion is 2026-01-01.
What conditions does trial NCT05375994 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Cancer, Metastatic Cancer, KRAS Activating Mutation, Malignant Neoplasm of Lung.
What interventions are being tested in trial NCT05375994?
The interventions under investigation include: avutometinib (VS-6766) and adagrasib (DRUG).
Who is sponsoring clinical trial NCT05375994?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05375994 being conducted?
This trial has 8 study locations across California, Colorado, Florida, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.